T-Cure, a startup selected for the Gyeongnam CCEI Startup Leap Package, has announced its plan to enter the global market within three years with its laser-based omnidirectional light-irradiating catheter fusion endoscopic treatment system.
The field of laser-based medical diagnostics and treatment is rapidly advancing and regarded as a core technology for future healthcare innovation. Lasers are used in diagnostics such as retinal exams, endoscopic microscopy, blood flow tests, and cancer detection. In treatment, applications include cosmetic dermatology, vision correction, varicose vein procedures, and targeted cancer surgery.
T-Cure’s endoscopic system overcomes the limitation of conventional straight-line optical fiber lasers by enabling 360-degree uniform irradiation. This feature is expected to improve symptoms of GERD (gastroesophageal reflux disease), a condition caused by weakened lower esophageal sphincter muscles, by promoting collagen regeneration through targeted laser stimulation.
Unlike complex surgical approaches such as sphincter resection or stitching, T-Cure’s solution can be performed under direct endoscopic vision, significantly lowering barriers for surgical treatment of GERD. Beyond GERD, the company envisions applications for type 2 diabetes, obesity, and hypertension, with clinical trials already underway at Asan Medical Center and Severance Hospital.
Targeting overseas markets first, T-Cure aims to establish itself in the U.S.-dominated global medical device industry. With regulatory and clinical hurdles ahead, the company expects its first product—set for release in 2027—to generate significant market impact. On this growth trajectory, T-Cure has been selected for the Ministry of SMEs and Startups’ Deep-tech TIPS program and also won the Governor of Gyeongnam Award (Excellence Prize) at the 2024 GO-SPACE IR Competition hosted by Gyeongnam CCEI.
CEO Kang Hyun-wook said, “Since our founding in 2020, we have always aimed at global markets. In three years, we will be standing shoulder to shoulder with leading global medical device companies, delivering innovative endoscopic treatment solutions that maximize both physician convenience and patient outcomes.”
Source: ET News (Busan Correspondent Noh Dong-kyun) Read the full article
T-Cure, a startup selected for the Gyeongnam CCEI Startup Leap Package, has announced its plan to enter the global market within three years with its laser-based omnidirectional light-irradiating catheter fusion endoscopic treatment system.
The field of laser-based medical diagnostics and treatment is rapidly advancing and regarded as a core technology for future healthcare innovation. Lasers are used in diagnostics such as retinal exams, endoscopic microscopy, blood flow tests, and cancer detection. In treatment, applications include cosmetic dermatology, vision correction, varicose vein procedures, and targeted cancer surgery.
T-Cure’s endoscopic system overcomes the limitation of conventional straight-line optical fiber lasers by enabling 360-degree uniform irradiation. This feature is expected to improve symptoms of GERD (gastroesophageal reflux disease), a condition caused by weakened lower esophageal sphincter muscles, by promoting collagen regeneration through targeted laser stimulation.
Unlike complex surgical approaches such as sphincter resection or stitching, T-Cure’s solution can be performed under direct endoscopic vision, significantly lowering barriers for surgical treatment of GERD. Beyond GERD, the company envisions applications for type 2 diabetes, obesity, and hypertension, with clinical trials already underway at Asan Medical Center and Severance Hospital.
Targeting overseas markets first, T-Cure aims to establish itself in the U.S.-dominated global medical device industry. With regulatory and clinical hurdles ahead, the company expects its first product—set for release in 2027—to generate significant market impact. On this growth trajectory, T-Cure has been selected for the Ministry of SMEs and Startups’ Deep-tech TIPS program and also won the Governor of Gyeongnam Award (Excellence Prize) at the 2024 GO-SPACE IR Competition hosted by Gyeongnam CCEI.
CEO Kang Hyun-wook said, “Since our founding in 2020, we have always aimed at global markets. In three years, we will be standing shoulder to shoulder with leading global medical device companies, delivering innovative endoscopic treatment solutions that maximize both physician convenience and patient outcomes.”
Source: ET News (Busan Correspondent Noh Dong-kyun) Read the full article